CDK

首页 / / / CDK

CDK 相关产品
CDK 亚型比较

全部(565) Inhibitor(65)

货号			产品名	纯度
A865044	现货	促	Lerociclib G1T38 is a potent, selective, and orally bioavailable CDK4/6 inhibitor with unique pharmacokinetic and pharmacodynamic properties, which result in high efficacy against CDK4/6 dependent tumors while minimizing the undesirable on-target bone marrow activity.	98%
A906291	现货	促	Enitociclib (+)-BAY-1251152 is a CDK9 inhibitor, Phase 1 of Neoplasms.	98%
A682750	现货	促	LY3177833 LY3177833 is an CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively.	99%+
A168683	现货	促	NU2058 NU2058 is a CDK inhibitor with IC50 of 17 μM and 26 μM for CDK2 and CDK1.	98%
A640056	现货	促	CDK-IN-2 CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of < 8 nM.	99%+
A1148285	现货	促	BSJ-03-123/BSJ-03-123游离态 BSJ-03-123 is a PROTAC selectively targeting on CDK6, consist of a warhead palbociclib (a CDK inhibitor) linked to a CRBN ligand pomalidomide.	98+%
A1264490	现货	促	YKL-5-124 YKL-5-124 is a highly selective, covalent CDK7 inhibitor with IC50 value of 9.7nM. It causes arrest at the G1/S transition and inhibition of E2F-driven gene expression, but resulted in no change to Pol II CTD phosphorylation.	99%+
A162125	现货	促	WHI-P180/WHI-P180，盐酸盐 WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 μM, respectively.	98%
A1365253	现货	促	T025 T025是一种具有口服活性的 Cdc2-like 激酶 (CLK) 抑制剂，对多种 CLK 激酶亚型的 Kd 值在纳摩尔级别 (如 CLK2 为 0.096 nM)。T025 可诱导 caspase-3/7 介导的细胞凋亡，适用于 MYC 驱动的肿瘤和细胞增殖异常的疾病研究。	99%+
A1598826	现货	促	WAY-383487 WAY-383487是一种 Tat 肽衍生物，能够抑制 HIV-1 长末端重复 (LTR) 激活转录。这使得 WAY-383487 在研究 HIV-1 复制及其转录调控机制中具有潜在应用价值。	95%
A1598756	现货	促	HS-243 HS-243是一种有效且选择性的IRAK-4和IRAK-1抑制剂，具有抗炎和抗癌活性，并对TAK1有微弱抑制作用，用于相关疾病研究。	95%
A1176931	现货	促	ON-013100 ON-013100是一种有丝分裂抑制剂，能够下调细胞周期蛋白 D1 (Cyclin D1) 的表达，具有抗肿瘤活性，适用于研究细胞周期调控和癌症治疗。	98%
A1157787	现货	促	Palbociclib-d8 Palbociclib-d8是一种选择性且口服活性的 CDK4/6 抑制剂，IC₅₀ 分别为 11 nM 和 16 nM，适用于 ER 阳性、HER2 阴性乳腺癌的研究。	98% +98%atom%D
A1210613	现货	促	CDK1-IN-2 CDK1-IN-2是一种特异性细胞周期蛋白依赖性激酶1（CDK1）抑制剂，IC50 为 5.8 μM。CDK1-IN-2 通过抑制CDK1的活性，阻止细胞从G2期过渡到M期，进而抑制细胞增殖，尤其是癌细胞的增殖。	98%+
A1173508	现货	促	CDK4/6-IN-2 CDK4/6-IN-2是一种强效的 CDK4 和 CDK6 双重抑制剂，IC₅₀ 分别为 2.7 和 16 nM。它通过阻断 CDK4/6 激活的细胞周期进展来抑制癌细胞增殖，特别是在乳腺癌和其他肿瘤中展现出广泛应用潜力。	98%
A1210582	现货	促	CAN508 CAN508是一种选择性 CDK9/cyclin T1 抑制剂，能够有效阻断 CDK9 活性，用于抗癌研究。	97%
A1229448	现货	促	CDK9-IN-15 CDK9-IN-15是一种有效的 CDK9 抑制剂，广泛应用于研究细胞周期调控和基因表达的相关机制，特别适用于癌症和细胞增殖调控的研究。	99%+
A1249640	现货	促	GW8510 GW8510是一种有效的细胞周期蛋白依赖性激酶 2 (CDK2) 抑制剂，能够阻断 CDK2 活性，并抑制核糖核苷酸还原酶 M2 (RRM2)。该化合物具有神经保护和抗癌活性，适用于与细胞周期调控及 DNA 合成相关的癌症研究。	98%
A1398865	现货	促	CDK9 inhibitor HH1 CDK9 抑制剂 HH1 是一种有效且选择性的 CDK9 抑制剂，用于癌症研究。	98%
A1537693	现货	促	PF-07220060 Narmafotinib在MDA-MB-231细胞中抑制了397Y-FAK的自磷酸化，IC50为7 nM，并且表现出低细胞毒性（IC50 = 2.7 μM，MDA-MB-231细胞）。	98%

产品名	Cdc ↓ ↑	CDK1 ↓ ↑	CDK19 ↓ ↑	CDK2 ↓ ↑	CDK3 ↓ ↑	CDK4 ↓ ↑	CDK5 ↓ ↑	CDK6 ↓ ↑	CDK7 ↓ ↑	CDK8 ↓ ↑	CDK9 ↓ ↑	CLK ↓ ↑	其他靶点	纯度
XL413 hydrochloride	++++ Cdc7, IC50: 3.4 nM													99%+
SU9516		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 22 nM		++ CDK4, IC50: 200 nM								99%+
RO-3306		+++ CDK1, Ki: 20 nM											SGK,ERK	98%
R547		++++ CDK1/CyclinB, Ki: 2 nM		++++ CDK2/CyclinE, Ki: 3 nM		++++ CDK4/CyclinD1, Ki: 1 nM								99%+
BMS-265246		++++ CDK1/CyclinB, IC50: 6 nM		++++ CDK2/CyclinE, IC50: 9 nM		+ CDK4/CyclinD, IC50: 230 nM								99%+
NU6027		+ CDK1, Ki: 2.5 μM		+ CDK2, Ki: 1.3 μM									DNA-PK	98%
Purvalanol A	++++ Cdc2/CyclinB, IC50: 4 nM			+++ CDK2/CyclinA, IC50: 70 nM CDK2/CyclinE, IC50: 35 nM		+ CDK4/CyclinD1, IC50: 850 nM								99%+
SCH900776				++ CDK2, IC50: 0.16 μM										99%+
AUZ 454				++++ CDK2(A144C), Kd: 9.7 nM CDK2(C118L), Kd: 18.6 nM										99%+
A-674563 HCl				++ CDK2, Ki: 46 nM									PKA	98%
JNJ-7706621		++++ CDK1/CyclinB, IC50: 9 nM		++++ CDK2/CyclinA, IC50: 4 nM CDK2/CyclinE, IC50: 3 nM	++ CDK3/CyclinE, IC50: 58 nM	+ CDK4/CyclinD1, IC50: 253 nM		++ CDK6/CyclinD1, IC50: 175 nM						99%+
AT7519		++ CDK1/CyclinB, IC50: 210 nM		++ CDK2/CyclinA, IC50: 47 nM	+ CDK3/CyclinE, IC50: 360 nM	++ CDK4/CyclinD1, IC50: 100 nM	+++ CDK5/p35, IC50: 13 nM	++ CDK6/CyclinD3, IC50: 170 nM			++++ CDK9/CyclinT, IC50: <10 nM			98+%
PHA-793887		++ CDK1/CyclinB, IC50: 60 nM		++++ CDK2/CyclinA, IC50: 8 nM CDK2/CyclinE, IC50: 8 nM		++ CDK4/CyclinD1, IC50: 62 nM	++++ CDK5/p25, IC50: 5 nM		++++ CDK7/CyclinH, IC50: 10 nM		++ CDK9/CyclinT1, IC50: 138 nM			99%+
Milciclib		+ CDK1/CyclinB, IC50: 398 nM		++ CDK2/CyclinA, IC50: 45 nM CDK2/CyclinE, IC50: 363 nM		++ CDK4/CyclinD1, IC50: 160 nM	+ CDK5/p35, IC50: 265 nM		++ CDK7/CyclinH, IC50: 150 nM					99%+
Kenpaullone		+ CDK1/CyclinB, IC50: 0.4μM		+ CDK2/CyclinA, IC50: 0.68μM CDK2/CyclinE, IC50: 7.5μM			+ CDK5/p35, IC50: 0.85μM							98%
SNS-032				+++ CDK2/CyclinA, IC50: 38 nM CDK2/CyclinE, IC50: 48 nM			+ CDK5/p35, IC50: 340 nM		++ CDK7/CyclinH, IC50: 62 nM		++++ CDK9/CyclinT, IC50: 4 nM			99%+
Dinaciclib		++++ CDK1, IC50: 3 nM		++++ CDK2, IC50: 1 nM			++++ CDK5, IC50: 1 nM				++++ CDK9, IC50: 4 nM			99%+
PHA-767491 hydrochloride	++++ Cdc7, IC50: 10 nM	+ CDK1, IC50: 250 nM		+ CDK2, IC50: 240 nM			+ CDK5, IC50: 460 nM				+++ CDK9, IC50: 34 nM		MK2	98%
(R)-Roscovitine	+ Cdc2/CyclinB, IC50: 0.65 μM			+ CDK2/CyclinA, IC50: 0.7 μM CDK2/CyclinE, IC50: 0.7 μM			++ CDK5/p35, IC50: 0.16 μM							99%+
Narazaciclib						++++ CDK4/CyclinD1, IC50: 3.87 nM		++++ CDK6/CyclinD1, IC50: 9.82 nM					RET	99%+
Palbociclib						++++ CDK4/CyclinD3, IC50: 9 nM CDK4/CyclinD1, IC50: 11 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%
Abemaciclib						++++ CDK4, IC50: 2 nM		++++ CDK6, IC50: 10 nM						99%
Ribociclib						++++ CDK4, IC50: 10 nM		+++ CDK6, IC50: 39 nM						98%
Palbociclib isethionate						++++ CDK4/CyclinD3, IC50: 9 nM CDK4/CyclinD1, IC50: 11 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%+
BS-181 HCl									+++ CDK7, IC50: 21 nM					99%+
(E/Z)-THZ1 dihydrochloride									++++ CDK7, IC50: 3.2 nM					99%+
LDC4297									++++ CDK7, IC50: 0.13 nM					99%+
Senexin A			+ CDK19, Kd: 0.31 μM							+ CDK8, Kd: 0.83 μM				98+%
MSC2530818										++++ CDK8, IC50: 2.6 nM				99%+
Wogonin											✔			99%+
Riviciclib HCl		++ CDK1/CyclinB, IC50: 79 nM		+ CDK2/CyclinA, IC50: 224 nM CDK2/CyclinE, IC50: 2.54 μM		++ CDK4/CyclinD1, IC50: 63 nM		+ CDK6/CyclinD3, IC50: 396 nM	+ CDK7/CyclinH, IC50: 2.87 μM		+++ CDK9/CyclinT1, IC50: 20 nM			99+%
LDC000067				+ CDK2, IC50: 2.441 μM							++ CDK9, IC50: 44 nM			98%
Flavopiridol		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 40 nM		+++ CDK4, IC50: 40 nM		+++ CDK6, IC50: 40 nM	+ CDK7, IC50: 300 nM		+++ CDK9, IC50: 20 nM			99%+
LY2857785									+ CDK7, IC50: 0.246 μM	+++ CDK8, IC50: 0.016 μM	+++ CDK9, IC50: 0.011 μM			99%+
AZD-5438		+++ CDK1, IC50: 16 nM		++++ CDK2, IC50: 6 nM							+++ CDK9, IC50: 20 nM			99%+
ML167												++ CLK4, IC50: 136 nM Dyrk1B , IC50: 1648 nM		99%+
(E/Z)-TG003												+++ mCLK1, IC50: 200 nM mCLK4, IC50: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

CDK 亚型特异性产品

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z